THTakayuki Hoshiyama

Takayuki Hoshiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takayuki Hoshiyama has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Jyunya Ako

    Department of Cardiovascular Medicine, Kitasato University School of Medicine, Japan

    1 shared publication
  • Koichiro Atsuda

    Pharmacy Practice and Science I, Research and Education Center for Clinical Pharmacy, Kitasato University School of Pharmacy, 1-15-1 Kitasato, Minami-Ku, Sagamihara, Kanagawa, 252-0375, Japan

    1 shared publication
  • Kunihiro Yamaoka

    Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Japan

    1 shared publication
  • Michinari Fukuda

    Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Japan

    1 shared publication
  • Minako Yamaoka-Tojo

    Department of Rehabilitation Sciences, Kitasato University Graduate School of Medical Sciences , Sagamihara

    1 shared publication
  • Ryo Kameda

    Department of Cardiovascular Medicine, Kitasato University School of Medicine, Japan

    1 shared publication

Latest Publications

  • Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital

    by Toshiaki Komatsu, Ryosuke Inagaki, Shintaro Azuma, Shunya Mochida, Yosuke Sato, Yoshinori Seto, Shin Nihonyanagi, Takayuki Hoshiyama, Tatsuhiko Wada, Yoko Takayama, et al.


  • Open Access

    Clinical and Microbiological Features of Asymptomatic SARS-CoV-2 Infection and Mild COVID-19 in Seven Crewmembers of a Cruise Ship

    by Takayuki Hoshiyama, Tatsuhiko Wada, Shin Nihonyanagi, Ryo Kameda, Minako Yamaoka-Tojo, Michinari Fukuda, Jyunya Ako, Kunihiro Yamaoka, Yoko Takayama

    Objective To describe the clinical features and clinical course of individuals diagnosed with asymptomatic SARS-CoV-2 infection or mild COVID-19. Patients The study participants consisted of 7 crewmembers of the passenger cruise-liner, Diamond Princess, who were admitted to our hospital after becoming infected with SARS-CoV-2 aboard the ship. Methods The data on patient background and biochemical test results were obtained from the patients' medical records. All patients had a chest X-ray, and a throat swab and sputum samples were sent for culture on admission. Results The median age of the 7 patients, of whom 4 were male and 3 were female, was 39 years (range: 23-47 years). On admission, none of them had fever, but 4 (57%) had a cough. None of them showed any signs of organ damage on laboratory testing. Chest X-ray showed pneumonia in one individual, which resolved spontaneously, while the other 6 had normal chest X-ray findings. Culture of throat swabs and sputum samples revealed that 4 patients (57%) had bacterial upper respiratory infections (Haemophilus influenzae, Klebsiella pneumoniae, and Staphylococcus aureus). The period from a positive PCR test to negative conversion ranged from 5 to 13 days, with a median of 8 days. Conclusion Healthy young adults without risk factors who acquire SARS-CoV-2 infection may have an asymptomatic infection or may experience mild COVID-19. In addition to obesity, an older age, underlying illness, and being overweight can lead to a risk of exacerbation; thus, hospital management for such individuals may be desirable. Culturing respiratory samples may be useful for diagnosing secondary bacterial pneumonia.


  • Differential influences of Fc gamma receptor blocking on the effects of certolizumab pegol and infliximab on human monocytes

    by Takayuki Hoshiyama, Yu Matsueda, Toshihiro Tono, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata

    Objectives: To compare the effects of certolizumab pegol (CZP) and infliximab (IFX) on human monocytes.Methods: Highly purified monocytes from healthy donors were cultured with CZP, IFX, control IgG1, or polyethylene glycol (PEG) at pharmacological attainable concentrations in culture medium with 10% autologous normal human serum (NHS) or with fetal bovine serum (FBS) for 24h, after which the supernatants were replaced by fresh culture medium containing LPS. After additional 24h of incubation, the supernatants were assayed for TNF- and IL-6. In some experiments, the cells were harvested after 1h of stimulation with LPS for analysis of mRNA for TNF- by quantitative PCR.Results: Pre-incubation of monocytes with CZP or IFX reduced the production of TNF- in subsequent cultures stimulated by LPS in a dose-dependent manner. The suppressive effects of IFX on the TNF- production were significantly diminished, but those of CZP were rather enhanced, in cultures with autologous NHS compared with in cultures with FBS. Addition of IgG, but not IgG F(ab)(2) fragments, significantly inhibited the suppressive effects of IFX on the production of TNF- and IL-6, whereas either IgG or IgG F(ab)(2) fragments had no significant influences on the suppressive effects of CZP. Furthermore, pre-incubation with CZP or IFX significantly inhibited the expression of mRNA for TNF- and IL-6 in monocytes compared with PEG or IgG.Conclusion: These results indicate that the mechanism of action of CZP is different from that of IFX. Thus, CZP suppresses the production of proinflammatory cytokines independently of Fc receptors, whereas the suppressive effects of IFX on human monocytes are almost totally dependent on the interaction with Fc receptors.